Pucotenlimab (HX008) is a humanized IgG4 monoclonal antibody that specifically targets the programmed cell death protein 1 (PD-1) immune checkpoint. it potently blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby restoring the ability of immune cells to target and eliminate cancer cells, Pucotenlimab can be used in studies about a wide range of solid tumours.